XW-10508 is under clinical development by XWPharma and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XW-10508’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XW-10508 overview

XW-10508 is under development for the treatment of major depressive disorder, treatment resistant depression and chronic pain. It is administered through oral route. The drug candidate acts by targeting both N-methyl-D-aspartate receptor (NMDA) and glutamate ionotropic receptor (AMPA).

XWPharma overview

XWPharma is a biopharmaceutical company that discovers and develops treatments for neurodegenerative diseases. The company’s pipeline products include valiloxybate a GABAB agonist NCE that treats ehlers-danlos syndrome (EDS) and cataplexy in narcolepsy non-motor symptoms of Parkinson’s disease; XW10508, a glutamatergic NMDA (N-methyl-D-aspartate) and AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) activator NCE to treat major depressive disorder and chronic pain. It has operations in the US and Taiwan. XWPharma is headquartered in Wuhan, Hubei, China.

For a complete picture of XW-10508’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.